scispace - formally typeset
K

Kai-Min Lin

Researcher at University of Cambridge

Publications -  14
Citations -  563

Kai-Min Lin is an academic researcher from University of Cambridge. The author has contributed to research in topics: Immunology & Medicine. The author has an hindex of 6, co-authored 8 publications receiving 222 citations. Previous affiliations of Kai-Min Lin include National Taiwan University.

Papers
More filters
Journal ArticleDOI

Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure

Catherine J. Reynolds, +125 more
- 14 Jun 2022 - 
TL;DR: B and T cell immunity against previous variants of concern was enhanced in triple vaccinated individuals, but magnitude of T and B cell responses against B.1.1 .1.529 spike protein was reduced.
Journal ArticleDOI

High-Definition Analysis of Host Protein Stability during Human Cytomegalovirus Infection Reveals Antiviral Factors and Viral Evasion Mechanisms.

TL;DR: A multiplexed approach to discover proteins with innate immune function on the basis of active degradation by the proteasome or lysosome during early-phase HCMV infection revealed that helicase-like transcription factor (HLTF), a DNA helicase important in DNA repair, potently inhibits early viral gene expression but is rapidly degraded during infection.
Journal ArticleDOI

CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants of Plasmodium falciparum invasion.

TL;DR: A robust in vitro culture system to produce RBCs that allow the generation of gene knockouts via CRISPR/Cas9 using the immortal JK-1 erythroleukemia line is reported, confirming the essential role for BSG during invasion.
Journal ArticleDOI

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Sim Lin Lin, +557 more
TL;DR: In this article , the authors report SARS-CoV-2 vaccine-induced immune responses and breakthrough infections in patients with inflammatory bowel disease, who are treated either with the anti-TNF antibody, infliximab, or with vedolizumab targeting a gut-specific anti-integrin that does not impair systemic immunity.